New Parkinson's disease treatment added to PBS

1 February 2023 - From 1 February, Australians with Parkinson’s disease will have access to a new medicine on the PBS. ...

Read more →

A watershed year for biosimilars — if regulators and policy makers step up

31 January 2023 - 31 January is set to mark the start of a watershed year for the biosimilars industry ...

Read more →

Schedule of Pharmaceutical Benefits - 1 February 2023

1 February 2023 - The February 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →

New Zealand Pharmaceutical Schedule - 1 February 2023

1 February 2023 - The February 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

Amjevita (adalimumab-atto), first biosimilar to Humira, now available in the United States

31 January 2023 - Four years of real world experience in more than 300,000 patients and over 60 countries. ...

Read more →

Call for Enhertu to be registered on Pharmaceutical Benefits Scheme

31 January 2023 - Sarah Lee has been forced to use her super and life insurance to pay for the treatment. ...

Read more →

Mum's push for cystic fibrosis treatment to be subsidised for children under 12

23 January 2023 - Mila was diagnosed with cystic fibrosis aged just one, after experiencing lung failure in hospital, and ...

Read more →

Pharmaceuticals campaigner moving to Australia after drug she desperately needs for spinal muscular atrophy is only funded for under 18s

22 January 2023 - This week, PHARMAC announced it was looking to fund a second drug to treat the neurological ...

Read more →

RemeGen announces two indications for anti-HER2 antibody drug conjugate disitamab vedotin included in China's National Reimbursement Drug List for 2023

20 January 2023 - RemeGen is pleased to announce that as of 18 January 2023, two indications for the Company's ...

Read more →

China's first and only approved third generation BCR-ABL inhibitor olverembatinib included into the 2022 National Reimbursement Drug List

18 January 2023 - Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the ...

Read more →

Assessing and extending California’s insulin manufacturing initiative

19 January 2023 - Set against the backdrop of current debates about lowering drug costs, lowering the price of insulin—a lifesaving ...

Read more →

Drugs added to reimbursement list

19 January 2023 - China will add 111 drugs to its national medical reimbursement list this year, with a focus ...

Read more →

Innovent announces inclusion in the China National Reimbursement Drug List of Tyvyt in two new indications, olverembatinib for the first listing, Byvadsa, Halpryza and Sulinno in multiple new indications

18 January 2023 - Innovent Biologics today announced that, five products (including new indications) of the company have been included in ...

Read more →

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of Tascenso ODT (fingolimod)

17 January 2023 - Tascenso ODT is now approved by the US FDA as a bioequivalent to Gilenya (fingolimod hydrochloride), for ...

Read more →

Zai Lab announces inclusion of Qinlock (ripretinib) and Nuzyra (omadacycline) in China’s National Reimbursement Drug List

18 January 2023 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...

Read more →